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Abstract
Background and study aims Although the Vienna Classi-
fication recommends endoscopic resection for gastric high-
grade dysplasia (HGD), many resected lesions are diag-
nosed as gastric cancer after endoscopic resection. This
study aims to evaluate the clinical outcomes of gastric
HGD identified by endoscopic forceps biopsy (EFB) after
endoscopic submucosal dissection (ESD) and factors
associated with discrepant results.
Patients and methods From December 2008 to July 2015,
a total of 427 lesions diagnosed as initial HGD by EFB
were enrolled. The rate of early gastric cancer (EGC) and
factors predicting diagnosis upgrade were analyzed
retrospectively.
Results Tumors ranged between 2 and 65 mm in size
(median 12.59). En bloc and complete resection rates were
97.4 and 95.3%, respectively. The diagnostic discrepancy
rate was 76.3%. Upgrade and downgrade rates of patho-
logical diagnoses were 66.5 and 9.8%, respectively. Cen-
tral depression (OR 4.151), nodular surface (OR 5.582),
surface redness (OR 2.926), lesion location (upper third of
the stomach) (OR 3.894), and tumor size C10 mm (OR
2.287) were significantly associated with EGC. Nodular
surface (OR 2.746), submucosal fibrosis (OR 3.958), lesion
location (upper third of the stomach) (OR 6.652), and
tumor size C10 mm (OR 4.935) significantly predicted
invasive submucosal cancer.
Conclusions Central depression, nodular surface, surface
redness, lesion location, large tumor size, and submucosal
fibrosis were associated with EGC or submucosal cancer.
Caution must be used in treating lesions with these features
with ESD.
Keywords Early gastric cancer  Dysplasia  Endoscopic
submucosal dissection  Biopsy
Introduction
In recent years, endoscopic submucosal dissection (ESD)
has become an accepted curative treatment modality for the
treatment of high-grade dysplasia (HGD) or early gastric
cancer (EGC) without lymph node metastasis. ESD is pre-
ferred because it is less invasive and expensive and results
in a better quality of life compared with surgical gastric
resection. In order to treat EGC by ESD, early detection of
EGC or dysplastic lesions is essential, especially in coun-
tries where gastric cancer is highly prevalent. In South
Korea, the National Cancer Screening Program is in oper-
ation and biennial esophago-gastro-duodenal endoscopy is
recommended for men and women over 40 years old. With
the widespread availability of screening endoscopy, early
detection of precancerous lesions and EGC has increased. In
South Korea, the proportion of stage IA patients has
increased by *57% during the last 10 years [1, 2].
Gastric adenoma/dysplasia is regarded as a precancerous
lesion. The risk of carcinoma generally increases with the
histological grade of the dysplasia (low to high grade) [3].
Gastric HGD (category 4 in the Vienna Classification) is
highly predictive of invasive carcinoma, which either
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coexists or appears within a short time after biopsy.
Therefore, from the revised Vienna Classification, HGD
should be removed by endoscopic resection [4]. Although
an endoscopic forceps biopsy (EFB) is the best method to
diagnose EGC, the misdiagnosis rate of EFB specimens for
gastric superficial neoplasm is reported to be up to 40–55%
[5, 6]. If the pathologic result after ESD subsequently
shows gastric cancer, additional surgical treatment may be
considered according to the pathological type (well vs.
poorly differentiated adenocarcinoma), depth of invasion
(mucosal cancer or submucosal invasive cancer or lym-
phatic invasion), or resection margin status (free resection
margin vs. involved resection margin). However, there is
no way to determine the submucosal or lymphatic invasion
accurately before endoscopic resection.
In the present study, we retrospectively evaluated the
final ESD outcomes of gastric HGD from EFB and ana-
lyzed the endoscopic characteristics associated with inva-
sive EGC after ESD.
Materials and methods
Patients
From December 2008 to July 2015, the medical records of
patients who were diagnosed with gastric HGD at the
Pusan National University Yangsan Hospital, South Korea,
were retrospectively reviewed. For patients diagnosed with
HGD at another institution and referred to our hospital for
treatment, endoscopic biopsy was performed again, and
tissue samples were re-analyzed.
In principle, endoscopic resection is recommended for
patients with a diagnosis of HGD. Among our study group,
two patients did not undergo endoscopic resection during
the study period because of underlying liver cirrhosis and
hepatocellular carcinoma, and an expected poor life
expectancy, although the patients continued to undergo
endoscopic assessment every 6 months for observation of
disease progression. Another three patients underwent
direct surgery despite confirmation of a diagnosis of HGD
on re-biopsy for the following reasons: One patient pre-
sented with a discursive ulcer, with a diagnosis of mucosal
cancer confirmed on surgical intervention. For another
patient, the lesion enclosed the whole cardia, with a diag-
nosis of invasive submucosal (SM) cancer without lymph
node metastasis. The third patient who underwent direct
surgery presented with a lesion with involvement from the
pyloric ring to the duodenum bulb, with three additional
adenomas in the antrum, conditions that increase the risk
for stenosis post-endoscopy. Once this was explained to the
patient, the patient accepted direct surgery, with the diag-
nosis of HGD being confirmed with surgery.
During the study period, 483 initial HGD lesions, con-
tributed by 457 patients, were managed by endoscopic
resection. Among these, 21 patients were lost to follow-up,
and 7 patients were transferred to another medical institu-
tion. In one patient, the pathological diagnosis of the lesion
was downgraded to low-grade dysplasia (LGD) at the time of
re-biopsy, followed by a 9-month follow-up period of
observation without further intervention. A negative patho-
logical report was also provided for another six lesions at the
time of re-biopsy, with three of these patients being lost to
follow-up after the negative diagnosis, while the remaining
three patients were followed up by observation. Ultimately,
the data from 427 initial HGD lesions, contributed by 401
patients, were included in our analysis (Fig. 1).
Written informed consent was obtained from all patients
prior to the procedure. The study was approved by the
ethics committee of the Institutional Review Board (Insti-
tutional Review Board no. 05-2016-040).
Endoscopic biopsy
Diagnostic endoscopy (using GIF-H260 or GIF-H290;
Olympus Optical Co., Ltd., Tokyo, Japan) and EFB were
performed in all patients before ESD. Most of the patients
were referred from other hospitals and underwent addi-
tional EFB or review of referred biopsy specimens.
ESD procedure
We performed ESD using the previously described tech-
nique [5]: after lesion marking, normal saline with an
epinephrine and indigocarmine mixture was injected into
the submucosal layer to elevate the lesion from the mus-
cularis propria. The mucosa surrounding the lesion was
then precut using an electrosurgical generator (ERBE VIO
300D, Endocut I mode, Effect 3, duration 2; Erbe Co,
Tubingen, Germany) with a flex knife, dual-knife, or an
insulation-tipped electrosurgical knife 2 (IT 2); lastly, the
connective tissue of the submucosa beneath the lesion was
dissected with a coagulation current (Swift coagulation 60
W, ERBE VIO 300D). After removal of the lesions, pre-
ventive post-ESD coagulation was performed for all visibly
exposed vessels with hot biopsy forceps.
Endoscopic and pathologic evaluation
Baseline characteristics and endoscopic findings of all
enrolled lesions were assessed. Endoscopic photographs
and endoscopic reports were reviewed to determine the
features of the lesions. All endoscopic diagnoses were
performed by two endoscopists (DG Ryu, MD, and SJ Kim,
MD), both of whom had received training on reviewing
approximately 100 typical endoscopic findings prior to
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assessment of the endoscopic biopsy images. All reviews
were performed in a blinded fashion. The diagnosis was
consistent between the two endoscopists for 382 of the 427
lesions. For the remaining 45 lesions, the diagnosis was
attained by discussion and consensus. The Paris Classifi-
cation was used to define the gross types of superficial
lesions, which were divided into elevated, flat, or depressed
[7]. Central depression, surface redness, nodularity, ulcer-
ation, and submucosa fibrosis were also evaluated. Central
depression was defined as the inner part of the lesion being
depressed compared to the surrounding, regardless of gross
type. Surface redness was defined as a red discoloration on
the mucosal surface of the lesion compared to the sur-
rounding mucosa. Surface nodularity was defined as the
presence of irregularly raised or nodular mucosa. Lesions
with ulcerations or scarring from previous ulceration
(converging folds or deformity of the muscularis propria or
fibrosis in the submucosa) were regarded as ulcerated. If
submucosa fibrosis was observed during the ESD proce-
dure, this was recorded with endoscopic pictures. The
location of lesions was described using the Japanese
Classification of Gastric Cancer [8]. In this system, the
gastric area is divided into three equal sections: the upper,
middle, and lower thirds of the stomach.
All of the endoscopically resected tissue slides were
blindly reviewed by two pathologists. Discordant cases
were re-evaluated under multi-headed microscope to reach
agreement. The resected specimens were stretched, pinned,
and fixed with formalin. Piecemeal-resected specimens
were reconstructed as much as possible. The fixed specimen
was sectioned at 2-mm intervals. All of the lesions were
measured on the length of the major and minor axes. All of
the lesions were classified as gastrointestinal epithelial
neoplasia according to the Vienna Classification [4].
Statistical analysis
Data were analyzed based on individual lesions because
some patients had multiple lesions. Univariate analysis
with chi-square test or Fisher’s exact test for categorical
variables and Student’s t test for continuous variables were
performed. Multivariate analysis with a multiple logistic
regression model was performed to identify risk factors for
EGC and furthermore submucosal or lymphovascular
invasive cancer. P\ 0.05 was considered statistically
significant. Statistical calculations were performed with
SPSS version 21.0 for Windows (SPSS Inc., Chicago, IL,
USA).
Results
The patients’ mean age was 63.89 ± 8.53 years. The range
of tumor size was 2–65 mm (median 12.59). The main
location of the lesions was the lower third of the stomach
(Table 1). En bloc resection and complete resection rates
were 97.4% (416/427) and 95.3% (407/427). The diag-
nostic discrepancy rate was 76.3% (326/427). The up- and
downgrade rates of the pathological diagnosis were 66.5%
(284/427) and 9.8% (42/427), respectively. Among those
undergoing EGC after ESD, 38 lesions were found to be
submucosal invasive lesions (including 6 with lympho-
vascular invasion). Among the submucosal invasive
lesions, 15 patients underwent additional operations, and
lymph node metastasis was found in 3 patients (Fig. 2).
Endoscopic characteristics associated with EGC were
analyzed (Table 2). Multivariate analysis revealed that
central depression [OR 4.151 (95% CI 2.340–7.363)],
nodular surface [OR 5.582 (95% CI 3.230–9.649)], surface
redness [OR 2.926 (95% CI 1.747–4.901)], lesion location
(upper third of the stomach) [OR 3.894 (95% CI
1.110–13.666)], and larger tumor size (C10 mm) [OR
2.287 (95% CI 1.387–3.770)] were significantly associated
with EGC. Multivariate analysis revealed that surface
nodularity [OR 2.746 (95% CI 1.246–6.053)], submucosal
fibrosis [OR 3.958 (95% CI 1.822–8.596)], lesion location
(upper third of the stomach) [OR 13.051 (95% CI
3.229–52.754)], and larger tumor size (C10 mm) [OR
6.652 (95% CI 2.357–18.772)] were significant factors
associated with submucosal invasive cancer (Table 3). A
case of diagnosis upgraded to deep submucosal invasive
cancer after ESD is illustrated in Fig. 3.
Fig. 1 Flow chart of the
enrolled lesions in this study.
ESD endoscopic submucosal
dissection, EFB endoscopic
forceps biopsy, HGD high-
grade dysplasia
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On follow-up at 3–6 months after endoscopic resection,
a Helicobacter pylori (HP) test (rapid urease test or biopsy
or blood antibody test or urea breath test) was performed in
all patients. Absence of infection was defined by two
consecutive negative HP test results, with one positive
result being considered as a case of infection. We identified
an incidence rate of HP infection of 58.1% (248/427 cases).
Among patients with no HP infection, 35.8% (64/179) of
patients had received prior HP treatment. However, there
was no difference in the rate of HP infection between the
final HGD group and EGC group. Moreover, there was no
difference in HP infection rate between the final HGD
group and SM invasive cancer group (Tables 2, 3).
Discussion
Since ESD has been widely implemented for the treatment
of EGC, early detection of precancerous lesions such as
HGD has been more important. In recent years, more than
50% of gastric cancers have been detected as EGC in South
Korea [1, 2]. Although EFB can be used as a basic diag-
nostic tool for the initial treatment of gastric superficial
neoplasm, gastric HGD (category 4 in the Vienna Classi-
fication) is shown to be cancer in about 27.6–80% of cases
after endoscopic resection [6, 9, 10]. The possible reasons
for this discrepancy may be as follows. First, forceps
biopsy samples are small and do not represent the entire
lesion. Second, cancer sometimes exists as hidden foci in
other parts of the lesion. Third, the atypia of adenoma and
adenocarcinoma is too subtle to detect in a small biopsy
specimen [6]. Fourth, accurate targeted biopsy through
EFB can be difficult because of the location of lesions. In
the present study, 66.5% (284/427) of lesions had the
diagnosis upgraded to EGC after ESD. Furthermore, 8.9%
(38/427) of lesions were diagnosed as submucosal invasive
cancer.
To accept ESD as a treatment of EGC, the risk of lymph
node metastasis must be absent. However, the presence of
lymph node metastasis can be confirmed after surgical
gastrectomy with lymph node dissection. EGC is a gastric
Table 1 Baseline characteristics
Total (n = 427)
Mean age [years (±SD)] 63.89 ± 8.53
En-bloc resection, n (%) 416 (97.4)
Complete resection, n (%) 407 (95.3)
Male, n (%) 337 (78.9)
Helicobacter pylori infection, n (%) 248 (58.1)




Central depression, n (%) 212 (49.6)
Nodular surface, n (%) 176 (41.2)
Surface redness, n (%) 215 (50.4)
Tumor location, n (%)
Upper third of stomach 26 (6.1)
Middle third of stomach 42 (9.8)
Lower third of stomach 359 (84.1)
Tumor size, n (%)
B10 mm 198 (46.4)
[10 mm 229 (53.6)
Range, mean size (mm) 2–65 (12.59)
Fig. 2 Final results of gastric high-grade dysplasia from endoscopic forceps biopsy. ESD endoscopic submucosal dissection, EFB endoscopic
forceps biopsy, HGD high-grade dysplasia, EGC early gastric cancer
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cancer limited to the mucosa or submucosa, irrespective of
the presence of lymph node metastasis. Submucosal and
lymphovascular invasions are independent risk factors for
lymph node metastases [11, 12]. Therefore, these findings
are critical prognostic factors in patients with EGC. Sub-
mucosal invasion has been reported as an independent risk
factor for lymphovascular invasion in endoscopically
resected EGC, and the incidence of lymph node metastasis
is significantly higher in submucosal invasive EGC [13].
This can be explained by the particular distribution of
lymph capillaries in the mucosal layer. Although lymph
capillaries are found in the deep lamina propria adjacent to
and within the muscularis mucosa, most large lymph ves-
sels are located in the submucosa [14]. However, there is
no way to precisely evaluate submucosal or lymphovas-
cular invasion before ESD. Recent reports examining the
long-term outcomes of endoscopic resection for EGC
(differentiated-type adenocarcinoma; no surface ulceration;
a diameter of B2 cm; limited to the mucosa) showed
comparable overall survival with surgery [15, 16]. For the
endoscopic treatment of EGC, Japanese [17] and South
Korean [18] gastric cancer treatment guidelines are almost
the same. According to the guidelines, ESD is indicated as
a standard treatment for lesions meeting the following
criteria (absolute indications): (1) lesions limited to the
mucosal layer, (2) well and/or moderately differentiated
adenocarcinomas, (3) tumors B2 cm in length, (4) absence
of ulceration or ulcer scar tissue, and (5) tumors without
lymphovascular involvement.
In the present study, risk factors associated with EGC
after ESD for HGD lesions were central depression,
nodular surface, surface redness, large tumor size (C1 cm),
and tumor location in the upper third of the stomach.
Additionally, associated factors with submucosal invasive
EGC were nodular surface, submucosal fibrosis, tumor
location in the upper third of the stomach, and larger tumor
size (C10 mm). As lesions progress, structural changes
appear. Central depression and a nodular surface are
associated with lesion progression [19]. Surface redness is
associated with the development of vascular structures with
disease progression [3]. Large tumor size is a known risk
factor for EGC in adenoma, which can be understood as the
size increases with disease progression [5]. However, we
do not definitely know why the location of a lesion in the
upper third of the stomach was a significant risk factor
associated with EGC. Before now, some studies have
shown that ESD is more difficult to treat and causes more
complications if the lesion is located in the upper portion of
Table 2 Characteristics and associated risk factors for upgrade diagnosis HGD to EGC in univariate and multivariate analysis (non-cancer,
n = 143/EGC, n = 284)
Variables Non-cancer, n (%) EGC, n (%) Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Age[60 86 (60.1) 196 (69.0) 1.476 0.971–2.244 0.068 1.477 0.887–2.457 0.134
Mean age [year ± (SD)] 62.69 ± 8.74 64.66 ± 8.32
Male gender 106 (74.1) 231 (81.3) 1.521 0.943–2.455 0.085 1.164 0.631–2.147 0.628
HP infection 81 (56.6) 167 (58.8) 1.093 0.728–1.640 0.670 1.082 0.657–1.783 0.758
Gross type
Elevated (ref.) 57 (39.9) 70 (24.6) 1.000 1.000
Flat 49 (34.3) 84 (29.6) 1.396 0.850–2.293 0.187 1.031 0.531–2.003 0.928
Depressed 37 (25.9) 130 (45.8) 2.861 1.726–4.744 \0.001 1.975 1.001–3.897 0.050
Central depression 39 (27.3) 173 (60.9) 4.156 2.681–6.443 \0.001 4.151 2.340–7.363 \0.001
Nodular surface 26 (18.2) 150 (52.8) 5.123 3.157–8.313 \0.001 5.582 3.230–9.649 \0.001
Surface redness 51 (35.7) 164 (52.8) 2.465 1.627–3.735 \0.001 2.926 1.747–4.901 \0.001
Ulcer 27 (18.9) 46 (16.2) 0.830 0.491–1.403 0.487 0.358 0.184–0.694 0.002
SM fibrosis 22 (15.4) 70 (24.6) 1.799 1.061–3.052 0.028 1.238 0.655–2.339 0.511
Tumor location
Lower (ref.) 127 (88.8) 232 (81.7) 1.000 1.000
Upper 4 (2.8) 22 (7.7) 3.011 1.015–8.929 0.038 3.894 1.110–13.666 0.034
Middle 12 (8.4) 30 (10.6) 1.369 0.677–2.766 0.381 1.604 0.714–3.601 0.252
Size[10 mm 58 (40.6) 171 (60.2) 2.218 1.472–3.341 \0.001 2.287 1.387–3.770 0.001
Mean size [mm ± (SD)] 10.52 ± 7.30 13.01 ± 8.39
HGD, high-grade dysplasia; EGC, early gastric cancer; SM, submucosa; HP, Helicobacter pylori
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the stomach [20]. A possible explanation for this is the
technical factors associated with the endoscopic experi-
ence. EGC located in the lower third of the stomach,
especially in the antrum, might be easily detected, but to
detect EGC in the upper third of the stomach, more prac-
tical experience with endoscopic procedures might be
required. Therefore, EGC lesions located in the upper third
of the stomach might have a delayed or missed diagnosis.
In addition, targeted biopsy of lesions located in the upper
third of the stomach is difficult. Further studies might be
required to clearly explain the reasons for this finding.
Furthermore, we found that 38 submucosal invasive can-
cers were wrongly diagnosed as HGD in this study (8.9%,
38/427). Risk factors associated with submucosal invasive
cancer were submucosal fibrosis, large tumor size, and
tumor location in the upper third of the stomach. Adeno-
carcinomas were more closely related to submucosal
fibrosis than were adenomatous lesions. A previous study
reported that fibroblasts and myofibroblasts cause fibrosis
of the submucosa as a result of the desmoplastic response
to cancers [21]. A previous study had shown that submu-
cosal invasive cancer causes submucosal fibrosis [22], and
our study also indicates that submucosal invasion is closely
related to submucosal fibrosis. As described above, lesions
located in the upper part of the stomach are difficult to find
and to perform targeted biopsy. Differences in wall
thickness according to the location in the stomach might be
associated with these results. The whole wall thickness is
thicker in the antrum than in the body and cardia, and the
thickness of the submucosal layer decreases from the
antrum to the cardia and the body [23]. Thus, an EGC
located in the upper portion of the stomach might be a deep
invasive cancer even though it is the same size.
There are several limitations to this study. First, it was
retrospectively conducted in a single center. The sample
size of lesions might be too small for supporting these risk
factors definitely. However, the identified risk factors,
including other studies so far, may be helpful for further
studies and provide evidence for caution with endoscopic
treatment of EGC. Second, we used the conventional
endoscopic appearances of the lesion for the analysis. If
recent diagnostic technologies such as IEE were used, more
accurate diagnoses may have been given.
In summary, because gastric HGD is a precancerous
lesion and has a high rate of diagnosis upgrading to EGC, it
should be removed. Risk factors associated with EGC were
central depression, nodular surface, surface redness, tumor
location (upper third of the stomach), and large tumor size.
Furthermore, if submucosal fibrosis is suspected, the
probability of submucosal invasive cancer increases.
Therefore, for lesions with these risk factors, physicians
should be cautious before deciding to treat with ESD.
Table 3 Risk factors associated with upgrade diagnosis HGD to SM or LV invasive cancer in univariate and multivariate analysis (reference,
n = 389/SM or LV invasive cancer, n = 38)
Variables Reference, n (%) SM cancer, n (%) Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Age[60 256 (65.8) 26 (68.4) 1.126 0.550–2.302 0.746 0.986 0.427–2.276 0.974
Mean age [year ± (SD)] 63.78 ± 8.32 65.19 ± 10.91
Male gender 308 (79.2) 29 (76.3) 0.847 0.386–1.861 0.680 0.529 0.209–1.342 0.180
HP infection 225 (57.8) 23 (60.5) 1.118 0.566–2.208 0.749 1.203 0.531–2.729 0.658
Gross type
Elevated (ref.) 112 (28.8) 15 (39.5) 1.000 1.000
Flat 126 (32.4) 7 (18.4) 0.415 0.163–1.054 0.058 0.443 0.150–1.314 0.142
Depressed 151 (38.8) 16 (42.1) 0.791 0.375–1.668 0.537 0.599 0.237–1.512 0.278
Central depression 189 (48.6) 23 (60.5) 1.623 0.822–-3.203 0.160 1.454 0.601-3.518 0.407
Nodular surface 153 (39.3) 23 (60.5) 2.365 1.196–4.676 0.011 2.746 1.246–6.053 0.012
Surface redness 190 (48.8) 25 (65.8) 2.014 1.001–4.052 0.046 1.974 0.890–4.379 0.094
Ulcer 64 (16.5) 9 (23.7) 1.576 0.712–3.3488 0.258 1.449 0.276–7.593 0.661
SM fibrosis 73 (18.8) 19 (50.0) 4.329 2.182–8.587 \0.001 3.958 1.822–8.596 0.001
Tumor location
Lower (ref.) 337 (86.6) 22 (57.9) 1.000 1.000
Upper 17 (4.4) 9 (23.7) 8.110 3.245–20.265 \0.001 6.652 2.357–18.772 \0.001
Middle 35 (9.0) 7 (18.4) 3.064 1.222–7.680 0.013 2.118 0.766–5.854 0.148
Tumor size[10 mm 196 (50.4) 33 (86.8) 6.499 2.485–16.996 \0.001 4.935 1.813–13.428 0.002
Mean size [mm ± (SD)] 11.86 ± 7.20 20.03 ± 11.65
HGD, high-grade dysplasia; SM, submucosa; LV, lymphovascular; HP, Helicobacter pylori
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Patients should also be informed of the risks and benefits of
undergoing more invasive treatments such as surgical
gastrectomy with lymph node dissection.
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